To the Editor-We have read with interest the excellent recent report by Putrianti et al [1] , in which infection treatment vaccination (ITV), with use of repeated vaccinations of mice with wildtype (WT) rodent malaria sporozoites followed by prophylactic primaquine (PQ) treatment, was used to induce sterile, lasting protective immunity against sporozoite challenge. PQ is a drug that kills parasite liver stages and, therefore, the authors concluded that persistence of liver stage parasites is not necessary to induce and maintain protective immunity. Furthermore, the authors noted that this differs fundamentally from vaccinations with irradiated sporozoites or genetically attenuated parasite (GAP) sporozoites, in which generation of an effective, lasting immune response depends on persistence of the parasite as liver stages. We respectfully disagree with the latter conclusion regarding GAPs.
Indeed, it has been shown that the degree of protection induced by vaccination with irradiated sporozoites can be diminished by treatment with PQ [2, 3] . It is difficult to directly evaluate the extent of this reduction, because different vaccination regimens, as well as different animal models, have been used over the years. In general, however, a reduction, rather than a total lack of protection, has been observed. For example, in one study [2] , WT irradiated Plasmodium berghei sporozoitevaccinated rats were treated with PQ. This resulted in a gradual loss of protection in the vaccinated rats: a 42% loss after 1 month and an 84% loss after 3 months.
In another study, 3 weekly doses of irradiated P. berghei sporozoites were used to vaccinate mice [3] . Treatment of vaccinated mice with PQ had no effect on protection when mice were challenged 1 week after the last vaccination, but if challenged 5 months after the last vaccination, 50% of the mice lost protection [3] . Some information is available for GAP persistence as a prerequisite to induce and maintain protective immunity. The authors of one study found that PQ treatment of GAPvaccinated mice led to a complete loss of protection when mice were challenged 1 month after the last vaccination [4] . However, persistence in the liver was not observed in a study using Plasmodium yoelii uis3 Ϫ GAPs [5] . Furthermore, the P. yoelii p52 Ϫ /p36 Ϫ GAP, which exhibits a severe defect in establishing a metabolically active liver stage and does not persist, also induces an effective immune response against WT challenge [6] . However, PQ was not used in these studies to assess its effect on protection.
To test whether liver stage persistence is necessary for GAP-induced protective immunity, we have designed an experiment in which BALB/c mice were vaccinated with P. yoelii uis3 Ϫ [5] or WT sporozoites in a regimen comparable to that used in the study by Putrianti et al [1] . Figure  1 ). Importantly, however, vaccination with uis3 Ϫ sporozoites followed by PQ treatment also resulted in complete protection against sporozoite challenge (Figure 1) . As a control, mice treated with only PQ did become patent after sporozoite challenge (Figure 1 ). This demonstrates that GAPs do not need to persist as liver stages to induce complete, lasting protective immunity. We conclude that the claim of a fundamental difference in the induction and maintenance of immune protection conferred by ITV versus GAP vaccination is untenable. It is likely that PQ treatment of WT parasite-inoculated mice creates a quasi-attenuated phenotype that is comparable to the phenotype described for GAPs (ie, early arrest in liver stage development and subsequent clearance of parasites from the liver) [5] . Does this imply that the expression of liver stage antigens does not significantly contribute to protection? We believe the answer is no, because even during the first 12 h of liver stage development, GAPs or WT parasites likely express many new antigens that can prime the immune response against liver stages. However, GAPs that arrest later in liver stage development, such as the recently described fatty acid biosynthesis mutants [7] , likely express additional proteins and might therefore generate a more diversified immune response that targets a wider variety of antigens. GAPs that arrest late in liver stage development might, 
